Company Information

ASTRAZENECA PHARMA INDIA LTD.

NSE : ASTRAZENBSE : 506820ISIN CODE : INE203A01020Industry : Pharmaceuticals & DrugsHouse : Astrazeneca Pharma India - MNC
BSE5271.00-48.75 (-0.92 %)
PREV CLOSE ( ) 5319.75
OPEN PRICE ( ) 5329.95
BID PRICE (QTY) 0.00 (0)
OFFER PRICE (QTY) 0.00 (0)
VOLUME 1009
TODAY'S LOW / HIGH ( )5261.00 5377.10
52 WK LOW / HIGH ( )3102 7208
NSE5328.4513.7 (+0.26 %)
PREV CLOSE( ) 5314.75
OPEN PRICE ( ) 5329.80
BID PRICE (QTY) 0.00 (0)
OFFER PRICE (QTY) 5328.45 (38)
VOLUME 7994
TODAY'S LOW / HIGH( ) 5255.00 5380.00
52 WK LOW / HIGH ( )3098 7220.95
ChairmanNarayan K Seshadri
Managing DirectorSanjeev Kumar Panchal
Company SecretaryManasa R
Non Executive DirectorAnkush Nandra
Hooi-Bien Chuah
Additional DirectorSylvia Lorena Varela Ramon
Non Executive Independent DirectorRevathy Ashok
Shilpa Shridhar Divekar
Whole Time DirectorBhavana Agrawal
Incorporation Year : 11-07 1979

Registered Office :

Address : Block N1, 12th Floor,Manyata Embassy Business Park,Rachenahalli, Outer Ring Road Bengaluru,
Karnataka-560045 .

Phone : 080 6774 8000

Industry : Pharmaceuticals & Drugs

Listing : BSE,NSE,MCX

© NIRMAL BANG. All rights reserved

Designed , Developed & Content Powered by Accord Fintech Pvt. Ltd.

Open an Account
FOR AFREE *DEMAT & BROKING ACCOUNT

Please fill in the details below

Close X

(Note - You will receive a call from our sales executive)

CLOSE X

RISK DISCLOSURES ON DERIVATIVES

  • 9 out of 10 individual traders in equity Futures and Options Segment, incurred net losses.
  • On an average, loss makers registered net trading loss close to ₹ 50,000.
  • Over and above the net trading losses incurred, loss makers expended an additional 28% of net trading losses as transaction costs.
  • Those making net trading profits, incurred between 15% to 50% of such profits as transaction cost.

Source:

1. SEBI study dated January 25, 2023 on “Analysis of Profit and Loss of Individual Traders dealing in equity Futures and Options (F&O) Segment”, wherein Aggregate Level findings are based on annual Profit/Loss incurred by individual traders in equity F&O during FY 2021-22.